Financings in Brief: Hepatix
This article was originally published in The Gray Sheet
Hepatix: Additional $3 mil. investment is secured from current shareholders including Chase Venture Capital Associates, Alta Partners and Woodland/Essex, the firm reports. Funds will be used for animal testing of the firm's ELAD extracorporeal liver assist device. The privately held company recently received state approval for its San Diego manufacturing facility, paving the way for production of the devices for use in human clinical trials. Studies in humans are anticipated to begin in late 1998, according to the firm...
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.